Navigation Links
Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
Date:3/18/2009

ectrical and Electronics Engineers, Inc. /National Institute of Health conference (IEEE/NIH) to be held on April 9, 2009 at the National Institute of Health in Maryland, USA.

The strategic alliance between Quest and IntelligentNano was made possible by financial and strategic support from the National Research Council's Industrial Research Assistance Program (NRC-IRAP).

Quest also announced today that it has received a one-year extension for the repayment of its $500,000 convertible debenture. The repayment of the debenture, which is exercisable at $0.25 per common share, was originally due on March 22, 2009. Payment is now due on March 22, 2010.

About the SonoLight Platform

SL017 and SL052 represent members of Quest's SonoLight Portfolio with the potential to reduce or eliminate the side effects associated with currently available cancer treatment modalities: surgery, chemotherapy and radiotherapy. Their properties of activation with harmless physical agents (light or ultrasound), combined with their ability to generate cancer vaccines and stimulate an anti-cancer immune response, warrant further development in a broad-spectrum oncology arena. Quest intends to initiate a Phase I trial to evaluate SL052 as a localized treatment for prostate cancer. Development of second generation drug delivery systems provides greater flexibility with regards to treatment of a wide variety of diseases throughout the body.

About Quest PharmaTech Inc.

Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platforms.

About IntelligentNano Inc.

IntelligentNano is a private company, founded by Dr. Jie Chen and Dr. Jame
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 Eisai Co., Ltd.,(Headquarters: Tokyo, President & ... of North America (Headquarters: New Jersey,the United States, ... in the schedule for submission to the U.S. ... Application (NDA) for E7389 (generic,name: eribulin mesylate) for ...
... 1 , - ENDORSE Global Findings Highlight ... VTE Management: Systematically Assess,Patient Risk for VTE and ... multinational study (Epidemiologic International Day for the,Evaluation of ... Acute,Hospital Care Setting) published today in the LANCET(1) ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced that ... community in New York City on Thursday, February 7,2008 ... be webcast live and available for replay on the,company,s ... CV Therapeutics, Inc., headquartered in Palo Alto, California, ...
Cached Biology Technology:Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 2Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 2The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 4CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... our cells migrate: nerve cells make their vital connections, ... organs, immune cells zero in to destroy pathogenic organisms, ... body. Scientists studying these migrations didn't know how cells ... Institute study has identified a fragment of a protein ...
... does matters after all. But for flying snakes, smaller ... In the May 15, 2005, issue of the Journal ... and behavior of flying snakes, and found that the ... of wing-like appendages, flying snakes are skilled aerial locomotors," ...
... Virginia Tech, has been awarded a Ralph E. Powe Junior ... his research on quorum sensing in bacteria. He is modeling ... by a bacteria colony once it has reached a critical ... to faculty members who are in the first two years ...
Cached Biology News:New understanding of cell movement may yield ways to brake cancer's spread 2Researchers reveal secrets of flying snakes 2Researchers reveal secrets of flying snakes 3Understanding how bacteria communicate may help scientists prevent disease 2Understanding how bacteria communicate may help scientists prevent disease 3
... a K-12 strain ideally suited as an ... transformation efficiency, blue/white screening capability (with appropriate ... in high yields of excellent quality plasmid ... potentially useful as a stringent host due ...
... Zealand White or Californian 8 - 10 ... 6 hours of collection, processed within 24 ... is then thawed in a cool waterbath, ... through a 0.22 micron filter, bottled, and ...
... Host Strain Competent Cell Sets Sets ... strain combinations The most common ... E. coli is to use chemically ... prepared in the laboratory, greater efficiency, reproducibility ...
... Imager delivers high resolution CCD confocal imaging ... effective optical package that fits on your ... combined with high quantum efficiency CCD cameras, ... recording at up to 100 fps. A ...
Biology Products: